The next generation biopharmaceuticals

Sobi announces phase I Complement Inhibitor program

2013-11-05

Sobi announces phase I Complement Inhibitor program

Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial today at the company’s Capital Markets Event in Stockholm.

SOBI002 is a small biologic molecule based on the Affibody® platform that works as a potent and selective inhibitor of complement protein C5, a key protein in human immunological and inflammatory processes and central to a number of important diseases.

“The advancement of SOBI002 into a phase I clinical trial marks an important milestone for Sobi”, said Geoffrey McDonough, CEO and President at Sobi. “It is a solid validation of our partnership-oriented biologics innovation model and could address a wide set of rare disease indications where C5 plays a role.”

“We believe that the Affibody® technology may offer a differentiated way to treat complement driven diseases, due to the small size, high solubility and stability of the molecule”, said David Bejker, CEO at Affibody. “Sobi is well positioned to take advantage of the potentially unique features of SOBI002 as they have an excellent skill-set to develop and commercialize biologics for rare diseases.”

The study will evaluate single and repeated doses of SOBI002 administered subcutaneously and intravenously in healthy volunteers. Sobi expects to be able to commence the clinical trial during the first quarter 2014.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Year-end report (February 24, 2017)